InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,835.60
(
0.99%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.58
(
-0.86%
)
Bitcoin
56,412.60
(
-0.99%
)
Post# of 21373
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dabullishbear

Send PM Follow Ignore
Followers 23
Posts 1725
Boards Moderated 0
Alias Born 09/03/2015

dabullishbear

Re: steadyhand post# 16648

Thursday, 02/22/2018 11:15:16 AM

Thursday, February 22, 2018 11:15:16 AM

Post# of 21373
OW*P ran from .002 to $3.23 from positive IRB approval and safety data for a medical marijuana cream for psoriasis. Market cap was damn near $500m. Innovation Pharmaceuticals ran from .15 up to $4.93 from positive phase I data with a market cap approaching $1B during that run. And I don't think Oncolix is just going to put out a PR that says phase I had no adverse effects. It's going to note efficacy if there is any, which it should given what we know about the last cohort. This will also be at an escalated dose too, meaning even more efficacy.

IMO
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up